newsfilter
← Latest News
GlobeNewswire·

Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson's Disease

Results from UB-312's Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, toda